Written Question · S5W-20773 · Session 5
What its position is on allowing interim access to the cystic fibrosis treatment, Orkambi, through the Cystic Fibrosis Trust’s clinical dat…
The question
To ask the Scottish Government what its position is on allowing interim access to the cystic fibrosis treatment, Orkambi, through the Cystic Fibrosis Trust’s clinical data registry.
The answer
There is an established process for licensed medicines to be appraised through the Scottish Medicines Consortium and we expect companies to follow this route. I am pleased that Vertex Pharmaceuticals have announced that it will make a new submission to the SMC for Orkambi.
Meantime, PACS Tier Two allows clinicians to apply for individual patient access to medicines which would otherwise be routinely unavailable to them, such as Orkambi. I welcome Vertex’s commitment to make Orkambi available to the NHS through PACS Tier Two at a discounted price and would strongly encourage clinicians to make use of this system if they judge this medicine as appropriate for their individual patient’s needs.
Meantime, PACS Tier Two allows clinicians to apply for individual patient access to medicines which would otherwise be routinely unavailable to them, such as Orkambi. I welcome Vertex’s commitment to make Orkambi available to the NHS through PACS Tier Two at a discounted price and would strongly encourage clinicians to make use of this system if they judge this medicine as appropriate for their individual patient’s needs.
In the Official Report
No contribution in the Official Report cites S5W-20773 by reference.